Maternal serum alpha-fetoprotein (MSAFP) is in pregnancies whose early mid-trimester MSAFP known to be elevated in fetal open neural tube values were greater than twice the median; these defects (NTD) [5, 7, 21, 24] . It is used as an early infants were appropriate but not small for gestascreening method for this condition when meas-tional age. ured between 15 and 20 weeks of gestation and is None of the reported studies has examined the likelytobecomearoutinepartofprenatalcare.lt overall relationship, if any between early midis also elevated in multiple pregnancies [23] , fetal trimester MSAFP and neonatal birth weight and demise [18] , threatened abortion [22] and other gestational age. The purpose of this study is to fetal abnormalities, such as omphalocele, fetal determine if such relationships exist and whether bowel obstruction [6] , congenital nephrotic syn-or not they may be useful in detecting risk for drome [17] , trisomy 13 with cystic hygroma and altered growth or preterm delivery. TURNER'S syndrome [13] . In the non-pregnant state, serum AFP is elevated in primary hepatoma [1], embryonal cell carcinoma of the ovary [12], ataxia telangectasia and hepatitis [19] . Elevated mid-trimester alpha-fetoprotein (MSAFP)
1 Matenals and methods in women carrying single, anatomically and karyotypically normal fetuses has been found to precede Venous blood was obtained from patients referred the birth of low birthweight infants. BROCK et al. for genetic counseling prior to clinically indicated [4] , found that the proportion of low birthweight amniocentesis between 15 and 20 weeks gestation infants less than 2.5 kg was significantly increased in the period between January 1980 and Decemwhen early mid-trimester MSAFP was greater than ber 1982. Informed consents were obtained from 2.3 (x median value). WALD et al. [25] , demon-all patients. Complete data including MSAFP strated that pregnancies with early mid-trimester values, neonatal birthweight, and estimated gesta-MSAFP greater than or equal to 3 (x median tional age at birth were available in 116 pregvalue), resulted in the birth of infants weighing on nancies. Indications for genetic counseling are the average 357 gms less than the controls. Also, included in Tab. I. One hundred and ten karyothe gestational age at the time of birth was 8 days typically and anatomically singleton pregnancy less than the controls. SMITH [20] on the other outcomes were evaluated; six cases were excluded hand, found that a statistically significant increase because of fetal demise (3 cases), trisomy 21 in the number of infants weighing less than 2.5 kg (1 case), trisomy X (1 case), twins (1 case). weeks gestation related to birthweight adjusted for gestational age ten-fold more strongly (R 2 = 6.3 %, ρ < 0.01) as shown in Fig. 1 than to gestational age alon (R 2 = .6 %, NS). Gestational age at amniocentesis was unrelated to fetal growth or pregnancy duration.
Discussion
This study demonstrates that there is a definite linear relationship between early mid-trimester MSAFP values and fetal growth, a mainly third trimester phenomenon. Early mid-trimester MSAFP values were not significantly related to gestational age at birth. Our study differs from those previously reported [3, 4, 20, 25] , in that all babies were included, so that any overall relationships could be detected, rather than simply to correlate their birthweight with early mid-trimester MSAFP values relating elevated MSAFP values to low birthweight. The majority of patients in this study were referrals (40 patients from our institution) for genetic counseling. They were, in general, not at increased risk for intrauterine growth retardation (IUGR). This is reflected in the distribution of their outcomes -85 appropriate for gestational age, 22 large for gestational age, and 3 small for gestational age.
The explanation for the key finding in this study remains speculative AFP is a predominant protein in fetal plasma and it reaches its highest concentration [9] at 12-15 weeks gestation. It is synthesized in the fetal liver [8] and the embryonal sac [10]; it passes by diffusion into the fetal urine and is excreted into the amniotic fluid. Some of the amniotic fluid AFP diffuses into the tnaternal circulation through the amnion while some is swallowed by the fetus. As pregnancy progresses, an increasing portion of the maternal serum AFP is derived by placental passage. While the amniotic fluid AFP declines as gestation proceeds, the level in maternal serum rises geometrically until 32 weeks when it begins to fall [9].
Nonetheless, the elevation of serum AFP in primary liver cancer in non-pregnant patients has been attributed to its increased production from undifferentiated cells [15] . Raised levels in nonmalignant liver disease during the recovery stages seems to be associated with regeneration of the liver cells; both in experimental liver damage in mice and after cessation of alcohol intake in cirrhotic patients, AFP levels have been found to be elevated [4] . This might offer an explanation for elevated early mid-trimester MSAFP and altered fetal growth; the liver is the first organ to be affected in growth retarded fetuses. This could be associated with a protective mechanism, in the form of multiplication or relatively undifferentiated embryonic cells which would produce increased amounts of AFP. This hypothesis could and should be tested. An alternative hypothesis to explain the relationship between MSAFP and fetal growth could be based on the observation of spontaneous fetalmaternal hemorrhaging and elevated early mid-trimester maternal serum alpha-fetoprotein, as reported by HAY [11] . We are currently examining this possibility.
Regardless of the precise mechanism, it is reasonable to conclude from the current results that early mid-trimester MSAFP determinations, likely to become a routine part of prenatal care for NTD screening, may also be of assistance in identification of fetuses at risk for altered growth. Early mid-trimester MSAFP does not appear to aid in the detection of preterm or postterm births. The utility of maternal serum alpha-fetoprotein for the antenatal detection of IUGR deserves further study.
Summary
Early mid-trimester screening of maternal serum alphafetoprotein (MSAFP) for the detection of neural tube defects is becoming a routine part of obstetrical care. In singleton pregnancies in the absence of fetal chromosomal abnormalities and anatomical anomalies high levels of AFP have been variably related to increased risk for low birthweight infant outcome. The overall relationship, if any, of maternal serum AFP to infant birthweight has, however, not been previously characterized. Between 15 and 20 weeks gestation, MSAFP values were determined for 110 women carrying single, anatomically and karyotypically normal fetuses. Statistical analysis utilizing polynomial and multilinear regression was used to determine the relationship of early mid-trimester MSAFP first to neonatal birthweight and then to gestational age and birthweight adjusted for gestational age. For every increase of one multiple of the median in MSAFP, neonatal birthweight fell 3 22 grams. This was accounted for almost entirely by decreased fetal growth; early midtrimester MSAFP was linearly related to birthweight adjusted for gestational age ten times more strongly than to gestational age alone. The explanation for this relationship remains speculative, but the utility of routine AFP screening for the antenatal detection of intrauterine growth retardation certainly deserves further study. 
